Cite

HARVARD Citation

    Tseng, C. et al. (2023). Safety and pharmacokinetic profile of apixaban in end‐stage renal disease: A real‐world analysis. EJHaem. 4 (1), pp. 291-293. [Online]. 
  
Back to record